Healthcare and life science shipments come with unique demands. Temperatures are precisely controlled. Conditions must be continuously monitored. And when lives are affected, delays are not an option.
Better meeting the needs of the healthcare and life sciences industries is one of UPS’s strategic priorities, and we are rapidly improving our technology and capabilities in this space, including the delivery of shipments to remote areas.
Innovations in medicine and medical technology are designed to serve the 600 million people living in the most developed countries, and that’s who they typically benefit. But what about the other 6 billion?
Multimedia with summary
On Wednesday, November 2nd, Andrew Witty, GSK CEO, will join Seth Berkley, GAVI Alliance CEO, at Fortune Brainstorm Health for a discussion on “The Other Six Billion” referring to the areas of the world that are traditionally not served by innovations in medicine and medical technology. Outside of the most developed countries infectious diseases—including malaria, tuberculosis and HIV—still kill an astounding 15 million people a year.
May 10, 2013 /3BL Media/ - GlaxoSmithKline (GSK) today announced a new commitment to the GAVI Alliance to supply its cervical cancer vaccine as part of a new long term programme to help protect girls against cervical cancer in the world’s poorest countries. To start the programme and over the next two years, GSK will supply doses of Cervarix® (Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)) to four new GAVI demonstration projects at a significantly discounted price of $4.60 per dose.